Dipeptedyl peptidase-4 (DPP-4) inhibitor downregulates HMGB1/TLR4/NF-κB signaling pathway in a diabetic rat model of non-alcoholic fatty liver disease

References

• Abo-Haded, H.M., et al., 2017. Hepatoprotective effect of sitagliptin against methotrexate induced liver toxicity. PLOS one, 12 (3), e0174295.
   PubMed Web of Science ®Google Scholar
• Akaslan, S.B., et al., 2013. Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats. Metabolic syndrome and related disorders, 11 (4), 243–250.
   PubMed Web of Science ®Google Scholar
• Alisi, A., et al., 2014. Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease. Expert review of molecular diagnostics, 14 (6), 763–771.
   PubMed Web of Science ®Google Scholar
• Andersson, U., Yang, H., and Harris, H., 2018. High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells. Seminars in immunology, 38, 40–48.
   PubMed Web of Science ®Google Scholar
• Bai, L. I., et al., 2016. Inhibition of the translocation and extracellular release of high-mobility group box 1 alleviates liver damage in fibrotic mice in response to D-galactosamine/lipopolysaccharide challenge. Molecular medicine reports, 13 (5), 3835–3841.
   PubMed Web of Science ®Google Scholar
• Balaban, Y.H., et al., 2007. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Annals of Hepatology, 6 (4), 242–250.
   PubMed Web of Science ®Google Scholar
• Baumeier, C., et al., 2017. Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease. Molecular metabolism, 6 (10), 1254–1263.
   PubMed Web of Science ®Google Scholar
• Cai, J., Zhang, X.-J., and Li, H., 2018. Role of innate immune signaling in non-alcoholic fatty liver disease. Trends in endocrinology and metabolism, 29 (10), 712–722.
   PubMed Web of Science ®Google Scholar
• Cawthorn, W.P. and Sethi, J.K., 2008. TNF-alpha and adipocyte biology. FEBS letters, 582 (1), 117–131.
   PubMed Web of Science ®Google Scholar
• El-Kashef, D.H. and Serrya, M.S., 2019. Sitagliptin ameliorates thioacetamide-induced acute liver injury via modulating TLR4/NF-KB signaling pathway in mice. Life sciences, 228, 266–273.
   PubMed Web of Science ®Google Scholar
• Fan, M., Li, Y., and Zhang, S., 2016. Effects of sitagliptin on lipid profiles in patients with type 2 diabetes mellitus: a meta-analysis of randomized clinical trials. Medicine, 95 (2), e2386.
   PubMed Web of Science ®Google Scholar
• Ganz, M., et al., 2015. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice. Journal of translational medicine, 13 (1), 193.
   PubMedGoogle Scholar
• Han, L.-P., et al., 2016. Protective effects of celastrol on diabetic liver injury via TLR4/MyD88/NF-κB signaling pathway in type 2 diabetic rats. Journal of diabetes research, 2016, 2641248.
   PubMed Web of Science ®Google Scholar
• Hasan, S.T., et al., 2014. Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice. Atherosclerosis, 232 (1), 40–51.
   PubMed Web of Science ®Google Scholar
• Hsieh, J., et al., 2010. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia, 53 (3), 552–561.
   PubMed Web of Science ®Google Scholar
• Ideta, T., et al., 2015. The dipeptidyl peptidase-4 inhibitor teneligliptin attenuates hepatic lipogenesis via AMPK activation in non-alcoholic fatty liver disease model mice. International journal of molecular sciences, 16 (12), 29207–29218.
   PubMed Web of Science ®Google Scholar
• Itou, M., et al., 2013. Dipeptidyl peptidase-4: a key player in chronic liver disease. World journal of gastroenterology, 19 (15), 2298–2306.
   PubMed Web of Science ®Google Scholar
• Jung, Y.-A., et al., 2014. Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis. Diabetes research and clinical practice, 105 (1), 47–57.
   PubMed Web of Science ®Google Scholar
• Li, L., et al., 2011. Nuclear factor high-mobility group box1 mediating the activation of toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology, 54 (5), 1620–1630.
   PubMed Web of Science ®Google Scholar
• Lin, F.-Y., et al., 2020. Dipeptidyl peptidase-4 inhibitor decreases allograft vasculopathy via regulating the functions of endothelial progenitor cells in normoglycemic rats. Cardiovascular drugs and therapy. doi:10.1007/s10557-020-07013-w
   Web of Science ®Google Scholar
• Livak, K.J. and Schmittgen, T.D., 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods, 25 (4), 402–408.
   PubMed Web of Science ®Google Scholar
• Lu, B., et al., 2014. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proceedings of the National Academy of Sciences of the United States of America, 111 (8), 3068–3073.
   PubMed Web of Science ®Google Scholar
• Lundbäck, P., et al., 2016. A novel high mobility group box 1 neutralizing chimeric antibody attenuates drug-induced liver injury and postinjury inflammation in mice. Hepatology, 64 (5), 1699–1710.
   PubMed Web of Science ®Google Scholar
• Luo, X., et al., 2018. Expression of STING is increased in liver tissues from patients with NAFLD and promotes macrophage-mediated hepatic inflammation and fibrosis in mice. Gastroenterology, 155 (6), 1971–1984.e4.
   PubMed Web of Science ®Google Scholar
• Ma, K.L., et al., 2008. Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. Hepatology, 48 (3), 770–781.
   PubMed Web of Science ®Google Scholar
• Ma, Z., et al., 2017. Beneficial effects of paeoniflorin on non-alcoholic fatty liver disease induced by high-fat diet in rats. Scientific reports, 7, 44819.
   PubMed Web of Science ®Google Scholar
• Matthews, D.R., et al., 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28 (7), 412–419.
   PubMed Web of Science ®Google Scholar
• McIntosh, C.H.S., et al., 2005. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regulatory peptides, 128 (2), 159–165.
   PubMedGoogle Scholar
• Mehal, W.Z., 2014. The inflammasome in liver injury and non-alcoholic fatty liver disease. Digestive diseases, 32 (5), 507–515.
   PubMed Web of Science ®Google Scholar
• Mihm, S., 2018. Danger-associated molecular patterns (DAMPs): molecular triggers for sterile inflammation in the liver. International journal of molecular sciences, 19 (10), 3104.
   PubMed Web of Science ®Google Scholar
• Mitra, S., De, A., and Chowdhury, A., 2020. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Translational gastroenterology and hepatology, 5, 16.
   PubMed Web of Science ®Google Scholar
• Miura, K., et al., 2010. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology, 139 (1), 323–334.e7.
   PubMed Web of Science ®Google Scholar
• Perry, R.J., et al., 2015. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell, 160 (4), 745–758.
   PubMed Web of Science ®Google Scholar
• Salmenniemi, U., et al., 2004. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation, 110 (25), 3842–3848.
   PubMed Web of Science ®Google Scholar
• Shen, T., et al., 2018. Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway. Experimental and therapeutic medicine, 16 (4), 3121–3128.
   PubMed Web of Science ®Google Scholar
• Takeuchi, M., et al., 2014. Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: novel treatment strategies. World journal of hepatology, 6 (12), 880–893.
   PubMedGoogle Scholar
• Uno, M., et al., 2008. Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis. Hepatology, 48 (1), 09–118.
   Web of Science ®Google Scholar
• Wang, N., et al., 2013. Expression and activity of the TLR4/NF-κB signaling pathway in mouse intestine following administration of a short-term high-fat diet. Experimental and therapeutic medicine, 6 (3), 635–640.
   PubMed Web of Science ®Google Scholar